Quantcast

Latest Insulin glargine Stories

2011-06-27 07:30:00

SAN DIEGO, June 27, 2011 /PRNewswire/ -- Ultra-long acting insulin degludec, under development by Novo Nordisk, lowers blood glucose levels with significantly reduced rates of hypoglycemia (low blood sugar) compared to insulin glargine, according to data presented at the 71st Scientific Sessions of the American Diabetes Association (ADA) in San Diego. Data were from two, phase three, 52-week clinical trials, one with individuals with type 1 and one in individuals with type 2 diabetes. To...

2011-06-27 00:00:00

PARIS, June 27, 2011 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today, at the 71st Scientific American Diabetes Association Sessions 2011, the results of three studies showing that people with diabetes using Sanofi insulins Lantus(R) and/or Apidra(R) with the insulin delivery device SoloSTAR(R) experienced greater treatment satisfaction, better quality of life and lower fear of hypoglycemia vs those using a premixed insulin product. The goal of the...

2011-06-24 16:15:00

PARIS, June 24, 2011 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today data from a 60-week, open-label study that compared three intensified insulin regimens added to oral therapy for uncontrolled type 2 diabetes and found that using two regimens including Lantus® (insulin glargine [rDNA origin] injection) and Apidra® (insulin glulisine [rDNA origin] injection) lowered blood glucose levels compared to premixed insulin with less...

2011-06-07 07:00:00

BRIDGEWATER, N.J., June 7, 2011 /PRNewswire/ -- Actors Paul and Mira Sorvino today announce the Diabetes Co-Stars: Cook-Off. This nationwide recipe contest runs from June 7-July 20, 2011 and is a continuation of their work with sanofi-aventis U.S. on the Diabetes Co-Stars awareness campaign, which is designed to help educate people living with diabetes and those who support them. To view the multimedia assets associated with this release, please click:...

2011-02-09 06:30:00

PARIS, Feb. 9, 2011 /PRNewswire/ -- Change on Q4 2010 a Change at ------- reported constant exchange basis rates ----- --------- Net sales EUR7,395m +0.5% -5.9% Business net income(1) EUR1,838m -0.3% -9.7%...

2010-12-07 22:19:38

A new study finds that combining the newer diabetes drug exenatide with insulin provides better blood sugar control in patients with type 2 diabetes than insulin alone and helps promote weight loss. "This study may be the best result ever for patients whose diabetes is inadequately controlled on a combination of pills and insulin," said John Buse, MD, PhD, lead author of the study and chief of the Division of Endocrinology and Metabolism in the University of North Carolina at Chapel Hill...

2010-09-30 05:58:00

COPENHAGEN, September 30, 2010 /PRNewswire/ -- Zealand Pharma A/S, the biopharmaceutical company dedicated to the discovery and development of innovative peptide-based drugs, is pleased to note that its partner, sanofi-aventis, has today announced positive top-line results of the Phase III GETGOAL-L-ASIA trial which assessed the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist discovered by Zealand Pharma, in combination with basal insulin. Results of the study...

2010-09-20 07:30:00

PARIS, Sept. 20 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today results of two studies presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden. The first pooled analysis using patient-level data from randomized clinical trials demonstrated that adding Lantus® (insulin glargine [rDNA] injection) to patients with type 2 diabetes, uncontrolled on oral antidiabetic drug therapy...

2010-06-26 09:05:00

PARIS, June 26 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today results of a study which demonstrated that patients using Lantus® (insulin glargine [rDNA origin] injection) once-daily and Apidra® (insulin glulisine [rDNA origin] injection) before meals reported improved patient reported outcomes and decreased glycemic variability versus premix analog insulin. Two abstracts from this study were highlighted at the...

2010-06-25 15:20:00

PARIS, June 25 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that results from the RAndomized Study of Basal Bolus Insulin Therapy in the Inpatient Management of Patients with Type 2 Diabetes Undergoing General Surgery (RABBIT-2 Surgery) found that treatment with a basal-bolus regimen that included Lantus® (insulin glargine [rDNA origin] injection) once-daily and Apidra® (insulin glulisine [rDNA origin] injection)...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.